Literature DB >> 29526476

Introduction: Uterine adenomyosis, another enigmatic disease of our time.

Jacques Donnez1, Olivier Donnez2, Marie-Madeleine Dolmans3.   

Abstract

Like endometriosis, uterine adenomyosis is another enigmatic disease and remains a source of controversy. Uterine adenomyosis is characterized by the presence of endometrial glands in the myometrium. Two main theories may explain its pathogenesis: adenomyosis may arise from invagination of the myometrial basalis into the myometrium; or an alternative theory maintains that it may result from metaplasia of displaced embryonic pluripotent müllerian remants or differentiation of adult stem cells. Uterine adenomyosis is responsible for pelvic pain, abnormal bleeding, and infertility. Its diagnosis may be improved by high quality imaging. This issue's Views and Reviews, authors stress the urgent need to establish some systematic classification. Medical and surgical strategies are discussed. It should be emphasized that treatment should be designed according to a patient's symptoms and an individual's needs. Surgical treatment remains a matter of debate. Indeed, the risk of uterine rupture during pregnancy after adenomyomectomy is a reality. Therefore, continued research into new molecules based on the pathogenic mechanisms is vital.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Adenomyosis; pathogenesis; therapy; uterine adenomyosis

Mesh:

Year:  2018        PMID: 29526476     DOI: 10.1016/j.fertnstert.2018.01.035

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

1.  RNA-seq reveals co-dysregulated circular RNAs in the adenomyosis eutopic endometrium and endometrial-myometrial interface.

Authors:  Zhengchen Guo; Hua Duan; Sha Wang; Sirui Wang; Qi Lin; Yazhu Li
Journal:  BMC Womens Health       Date:  2022-07-15       Impact factor: 2.742

2.  Establishment of a novel mouse model of adenomyosis suitable for longitudinal and quantitative analysis and perinatal outcome studies.

Authors:  Mohammed Elsherbini; Kaori Koga; Takehiro Hiraoka; Keiichi Kumasawa; Eiko Maki; Erina Satake; Ayumi Taguchi; Tomoko Makabe; Arisa Takeuchi; Gentaro Izumi; Masashi Takamura; Miyuki Harada; Tetsuya Hirata; Yasushi Hirota; Osamu Wada-Hiraike; Yutaka Osuga
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

3.  Talin1 Induces Epithelial-Mesenchymal Transition to Facilitate Endometrial Cell Migration and Invasion in Adenomyosis Under the Regulation of microRNA-145-5p.

Authors:  Yi-Yi Wang; Hua Duan; Sha Wang; Yong-Jun Quan; Jun-Hua Huang; Zheng-Chen Guo
Journal:  Reprod Sci       Date:  2021-02-04       Impact factor: 3.060

4.  A comparison of surgical outcomes between robot and laparoscopy-assisted adenomyomectomy.

Authors:  Jung In Shim; Eun-Hye Jo; Miseon Kim; Mi Kyoung Kim; Mi-La Kim; Bo Seoung Yun; Seok Ju Seong; Yong Wook Jung
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  A new trick for an old dog: The application of mifepristone in the treatment of adenomyosis.

Authors:  Xuan Che; Jianzhang Wang; Jiayi He; Qin Yu; Wenting Sun; Shuyi Chen; Gen Zou; Tiantian Li; Xinyue Guo; Xinmei Zhang
Journal:  J Cell Mol Med       Date:  2019-12-08       Impact factor: 5.310

Review 6.  Origin and Pathogenic Mechanisms of Uterine Adenomyosis: What Is Known So Far.

Authors:  Christina Anna Stratopoulou; Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Reprod Sci       Date:  2020-10-22       Impact factor: 3.060

7.  Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis.

Authors:  Xue Shen; Hua Duan; Sha Wang; Lu Gan; Qian Xu; Jin-Jiao Li
Journal:  Biomed Res Int       Date:  2019-01-20       Impact factor: 3.411

8.  Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of Administration.

Authors:  Jacques Donnez; Olivier Donnez; Jean Tourniaire; Michel Brethous; Elke Bestel; Elizabeth Garner; Sébastien Charpentier; Andrew Humberstone; Ernest Loumaye
Journal:  J Clin Med       Date:  2021-12-10       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.